KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Debt Ratio (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Debt Ratio for 7 consecutive years, with 0.46 as the latest value for Q4 2025.

  • Quarterly Debt Ratio rose 9.2% to 0.46 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.46 through Dec 2025, up 9.2% year-over-year, with the annual reading at 0.46 for FY2025, 9.2% up from the prior year.
  • Debt Ratio hit 0.46 in Q4 2025 for Royalty Pharma, down from 0.46 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.46 in Q3 2025 to a low of 0.36 in Q2 2021.
  • Historically, Debt Ratio has averaged 0.41 across 5 years, with a median of 0.41 in 2022.
  • Biggest five-year swings in Debt Ratio: fell 12.26% in 2023 and later grew 13.67% in 2025.
  • Year by year, Debt Ratio stood at 0.41 in 2021, then rose by 2.91% to 0.42 in 2022, then fell by 11.51% to 0.37 in 2023, then grew by 11.54% to 0.42 in 2024, then grew by 9.2% to 0.46 in 2025.
  • Business Quant data shows Debt Ratio for RPRX at 0.46 in Q4 2025, 0.46 in Q3 2025, and 0.44 in Q2 2025.